Accelerating Drug Discovery, Delivering Breakthroughs

Proven drug discovery leader with over 20 years of experience advancing innovative therapies from concept to clinic. Track record includes 8 IND filings and one FDA-approved medicine (Revumenib), with deep expertise across small molecules, peptide therapeutics, and emerging modalities.I have led programs from target validation through hit identification and optimization, using cutting-edge approaches such as SBDD, FBDD, HTS, DEL, and non-classical modalities including PROTACs, molecular glues, covalent inhibitors, and allosteric modulators. My peptide experience spans enkephalin analogs, VLA4 antagonists, and PCSK9 inhibitors.T herapeutic expertise covers a broad range of diseases—Alzheimer’s, Parkinson’s, stroke, neuropathic pain, cancer, immunology, virology, and osteoporosis—working on diverse targets including proteases, GPCRs, ion channels, PPIs, and inflammasomes. I have consistently addressed key challenges in potency, selectivity, ADME, cardiovascular liabilities, and toxicity, leading to successful development candidates.In addition to discovery science, I have optimized synthetic routes for bulk API production and directed outsourcing/scale-up strategies. I bring strong interdisciplinary knowledge across biophysics, pharmacology, biology, ADME, and formulation. I am an inventor on 30 issued U.S. patents with 40 additional applications pending.

Leadership & Business Impact

10+ years of leadership experience, managing multidisciplinary teams (chemistry, DMPK, pharmacology) in matrix environments.
Directed programs resulting in $500M in upfront deal value and over $2B in potential milestones.
Extensive experience managing strategic collaborations (e.g., Boehringer Ingelheim, Merck) and external CRO networks (chemistry, DMPK, HTS).
Skilled in setting R&D strategy, budget, and timelines, ensuring on-time delivery of milestones.
Certified in Project Management and QA/RA for drug development, bridging science with regulatory and business objectives.

Who We Are

At ShankarV Rx LLC, we bring over 20 years of proven leadership in drug discovery. From 7 IND filings to an FDA-approved therapy (Revumenib), we’ve successfully advanced programs across oncology, neurology, immunology, and metabolic diseases. Our consulting services are designed to help you overcome bottlenecks, optimize strategies, and maximize R&D investments.

What We Do

Target Selection & Validation
Confidently choose the right targets with in-depth scientific and clinical assessments.
Hit Identification & Optimization
Expertise in SBDD, FBDD, HTS, DEL, and cheminformatics to find high-quality leads quickly.
Lead Optimization
Driving molecules to candidates through SAR, potency, selectivity, and ADMET balance.
Preclinical Strategy
Translational study design that bridges discovery with IND-enabling development.
Innovative Modalities
PROTACs, molecular glues, cyclic peptides, covalent/allosteric modulators.
Data & Portfolio Review
Integrating chemistry, biology, DMPK, and safety to prioritize next steps.

Why Work With Us-Proven Impact

✅ 7 INDs Filed
✅ 1 FDA-Approved Drug
✅ $700M+ in upfront deals
✅ $2B+ in milestone potential
✅ 20+ years of global pharma & biotech leadership

Testimonials / Client Success

“ShankarV Rx LLC provided the clarity and strategy we needed to push our lead program forward. Their insights into medicinal chemistry and translational strategy were invaluable.”

— Biotech CEO, Oncology

Shankar is one of the most creative Chemists I met in my career as Medicinal Chemist. He has a deep understanding of all aspects of Drug Discovery including drug design, SAR, synthesis, pharmacology, pharmacokinetics and selecting the right molecules for profiling. It was a pleasure to work with him. He is a team player, excellent communicator and is driven by project success.

—-
Klaus Fuchs: Senior Research Project Leader at Boehringer Ingelheim Pharma